viewKazia Therapeutics Ltd

Kazia Therapeutics progresses phase II clinical trial for brain cancer drug

There is a global need for new therapies to more effectively treat brain cancer.

multiple medical images of the human brain
It is anticipated that the study will provide an initial data read-out in early calendar 2019

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has commenced an international phase II clinical trial of its lead program, GDC-0084, a developing brain cancer drug.

GDC-0084 is being developed for glioblastoma multiforme, the most common and most aggressive form of primary brain cancer.

Chemotherapy treatment temozolomide is only effective in one-third of patients.

Furthermore, the median survival rate is 12 to 15 months from diagnosis, meaning there is a demand in the market for superior treatments.

Kazia’s CEO Dr James Garner said: “The need for new therapies in this disease remains immense, and we believe that GDC-0084 may have a valuable role to play in improving outcomes for patients with glioblastoma.”

FDA grant in February paved way for phase II clinical trial

Commencement of the trial follows the decision of the US FDA to grant orphan drug designation to GDC-0084 in glioblastoma in February 2018.

This phase II study will initially be conducted predominantly at leading US-based centres.

The study will commence screening patients after the Easter holidays.

It is anticipated that the study will provide an initial data read-out in early calendar 2019.

Phase II builds on a successful phase I study

Kazia licensed GDC-0084 in late 2016 from Genentech, a member of the Roche Group, where it had previously completed a phase I clinical study in 47 patients with advanced glioma.

Genentech’s phase I study demonstrated a favourable safety profile and provided signals of efficacy.

Genentech also conducted an extensive preclinical program which showed encouraging results for GDC-0084 in animal models of glioblastoma.

Two clinical-stage programs

Kazia is an emerging cancer-focused biotech with two clinical-stage programs.

As well as GDC-0084, Kazia is developing Cantrixil to treat ovarian cancer which is currently in phase I trial.

Kazia expects a read-out of maximum tolerated dose and safety from its phase I study in ovarian cancer in the current June half.

Quick facts: Kazia Therapeutics Ltd

Price: 0.93 AUD

Market: ASX
Market Cap: $67.12 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...


Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott following the news it's been awarded US Food and Drug Administration (FDA) Fast Track Designation (FTD) for Paxalisib for the treatment of glioblastoma – the most common and aggressive form...

on 21/8/20

2 min read